New Chimeric Antigen Receptor Design for Solid Tumors

Frontiers in Immunology

Jiao Yang¹  Yiwei Chu¹  Yuedi Wang¹  Feifei Luo²  Chujun Zhao⁴ 

[1] Biotherapy Research Center, Fudan University, Shanghai, China;Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China;Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China;Northfield Mount Hermon School, Mount Hermon, MA, United States;

关键词: chimeric antigen receptor T-cell;    immunotherapy;    solid tumor;    adoptive T-cell therapy;    tumor microenvironment;   

DOI  :  10.3389/fimmu.2017.01934

来源: DOAJ

【 摘 要 】

In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy for solid tumors has not reached its full potential because of the lack of specific tumor antigens and inhibitory factors in suppressive tumor microenvironment (TME) (e.g., programmed death ligand-1, myeloid-derived suppressor cells, and transforming growth factor-β). In this review, we include some limitations in CAR design, such as tumor heterogeneity, indefinite spatial distance between CAR T-cell and its target cell, and suppressive TME. We also summarize some new approaches to overcome these hurdles, including targeting neoantigens and/or multiple antigens at once and depleting some inhibitory factors.

【 授权许可】

Unknown